Immunicon Corporation Presented Advances in Rare Cell Technology at ISAC XXIV International Congress, May 17-21, 2008

Immunicon Corporation (OTCBB:IMMC) made several presentations at the International Society for Analytical Cytology (ISAC) XXIV International Congress on advances in rare cell detection ranging from enhancements on CellTracks® imagery and enrichment technology; the elimination of operator variability by automating F.I.S.H. probe counting in circulating tumor cells; the ability to identify RSV infections in nasopharyngeal samples; and the monitoring of CD4 counts in HIV patients with a portable image cytometer. ISAC is the leading professional organization for scientists developing and utilizing multidisciplinary, advanced technology for the measurement of cells and cell processes. The annual meeting was held on May 17-21, 2008 in Budapest, Hungary. Leon W.M.M. Terstappen, Immunicon’s Senior Vice President, Research & Development and Chief Scientific Officer commented, "The research presented holds the future promise for simplified infectious disease testing and improvements to our tumor cell detection technology that would permit complete automation thereby eliminating operator error. This research has important implications in the fight against serious diseases." Following the conference, the presentations were posted on Immunicon’s Web site at http://www.immunicon.com. For more about the ISAC XXIV International Congress, visit http://www.isac-net.org/congress2008. Oral Presentations   Evaluation of an affordable and easy-to-use single platform image cytometer for CD4 and CD8 enumeration on HIV infected Thai patients Xiao Li, Christian Breukers1, Aurel Ymeti, Kovit Pattanapanyasat, Kasama Sukapirom, Leon W.M.M. Terstappen, Jan Greve.   Simulation of spectral imaging methods to measure aneuploidy Sjoerd T. Ligthart, Jan Greve, Leon W.M.M. Terstappen.   Poster Presentations Automatic FISH Probe Counting on Circulating Tumor Cells Sjoerd T. Ligthart , Joost F. Swennenhuis , Ronald Sipkema, Jan Greve, Arjan G.J. Tibbe, Leon W.M.M. Terstappen.   Characterization of Circulating Tumor Cells By Image Cytometry Frederik Schreuder, Tycho M. Scholtens , Sjoerd T. Ligthart, Arjan G.J. Tibbe, Joost Swennenhuis , Jan Greve, Leon W.M.M. Terstappen.   Improved Imaging of Immunomagnetically Enriched Rare Cells Tycho Scholtens, Frederick Schreuder, Jan Greve, Arjan Tibbe, Leon W.M.M. Terstappen.   Image Analysis Algorithm for HIV Monitoring By Image Cytometry Christian Breukers1, Xiao Li, Aurel Ymeti, Jan Greve1, Kovit Pattanapanyasat, Leon W.M.M. Terstappen.   Counting Virally Infected Cells in Nasopharyngeal Samples by Image Cytometry Frank Coumans, Leo Grady, Chandra Rao, Jimmy Page, Mark Connelly, Leon Terstappen. About Immunicon Corporation Immunicon Corporation is developing and commercializing proprietary cell- and molecular-based human diagnostic and life science research products, and is providing certain analytical services to pharmaceutical and biotechnology companies to assist them in developing new therapeutic agents, with an initial focus on cancer disease management. Immunicon has developed platform technologies to identify, count and characterize a small number of rare cells in blood, such as circulating tumor cells and circulating endothelial cells that are important in many diseases and biological processes. Immunicon’s products and underlying technology platforms also have application in cancer research and may have applications in other fields of medicine, such as cardiovascular and infectious diseases. For more information, please visit www.immunicon.com. Forward-Looking Statements This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are often preceded by words such as "hope,” "may,” "believe,” "anticipate,” "plan,” "expect,” "intend,” "assume,” "will” and similar expressions. Forward-looking statements contained in this press release include, among others, statements regarding the anticipated clinical utility and future promise of Immunicon’s products and research and other statements not of historical fact. Immunicon cautions investors not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release, are based on the current expectations and intent of the management of Immunicon and involve certain factors, such as risks and uncertainties that may cause actual results to be far different from those suggested by these statements. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict, including, but not limited to, risks and uncertainties associated with: Immunicon’s ability to continue as a going concern; Immunicon’s dependence on Veridex, LLC, a Johnson & Johnson company; the risks and uncertainties with the arbitration proceeding with Veridex and the award in favor of Veridex given Immunicon’s dependencies on Veridex; the ability to earn license and milestone payments under Immunicon’s agreement with Veridex; Immunicon’s capital and financing needs; research and development and clinical trial expenditures; commercialization of product candidates; Immunicon’s ability to obtain licenses from third parties to commercialize products; Immunicon’s ability to manage its growth; obtaining necessary regulatory approvals; reliance on third party manufacturers and suppliers; reimbursement by third party payors to Immunicon’s customers; compliance with applicable manufacturing standards; retaining key personnel; delays in the development of new products or planned improvements to products; effectiveness of products compared to competitors’ products; protection of Immunicon’s intellectual property; conflicts with third party intellectual property; product liability lawsuits that may be brought against Immunicon; labor, contract or technical difficulties; and competitive pressures in Immunicon’s industry. These factors are discussed in more detail in Immunicon’s filings with the Securities and Exchange Commission. Except as required by law, Immunicon accepts no responsibility for updating the information contained in this press release beyond the published date, whether as a result of new information, future events or otherwise, or for modifications made to this document by Internet or wire services. "Immunicon,” "CellTracks” and the Immunicon Corporation logo are registered trademarks of Immunivest Corporation, a subsidiary of Immunicon Corporation. Repeat-Free is a trademark of Immunivest Corporation. Poseidon is a trademark of Kreatech Diagnostics. ALL RIGHTS RESERVED.